{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:14:33Z","timestamp":1773454473585,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jhep.2024.12.033","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T07:25:56Z","timestamp":1737357956000},"page":"771-772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antiviral treatment of chronic hepatitis D virus infection: To combine or not to combine?"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4425-2640","authenticated-orcid":false,"given":"Lisa","family":"Sandmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jhep.2024.12.033_bib1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jhep.2024.05.001","article-title":"Bulevirtide monotherapy in patients with chronic HDV: efficacy and safety results through week 96 from a phase III randomized trial","volume":"81","author":"Wedemeyer","year":"2024","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.12.033_bib2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A phase 3, randomized trial of bulevirtide in chronic hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jhep.2024.12.033_bib3","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jhep.2022.05.023","article-title":"Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread","volume":"77","author":"Zhang","year":"2022","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.12.033_bib4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL Clinical Practice Guidelines on hepatitis delta virus","volume":"79","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.12.033_bib5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa2314134","article-title":"Bulevirtide combined with pegylated interferon for chronic hepatitis D","volume":"391","author":"Asselah","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2024.12.033_bib6","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/S0168-8278(24)00563-4","article-title":"OS-122 Bulevirtide in combination with pegylated interferon alfa-2a shows a sustained off-treatment response in the liver. EASL congress 2024, OS-122","volume":"80","author":"Allweiss","year":"2024","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.jhep.2024.12.033_bib7","article-title":"Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide","volume":"6","author":"El Messaoudi","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.12.033_bib8","doi-asserted-by":"crossref","first-page":"S802","DOI":"10.1016\/S0168-8278(24)02220-7","article-title":"WED-410 Sustained virological response after treatment with Bulevirtide in HDV patients. Data from the French multicenter real-life cohort. EASL congress 2024, WED-410","volume":"80","author":"de L\u00e9dinghen","year":"2024","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.12.033_bib9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/apt.16945","article-title":"Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a \u201creal world\u201d study","volume":"56","author":"Jachs","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.jhep.2024.12.033_bib10","article-title":"Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression","volume":"5","author":"Jachs","year":"2023","journal-title":"JHEP Rep"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824028204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824028204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T01:20:54Z","timestamp":1773451254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824028204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0168827824028204"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.12.033","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral treatment of chronic hepatitis D virus infection: To combine or not to combine?","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.12.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}